Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The EUnetHTA 21 Consortium will cease operations on 16 September 2023

As announced some months ago, the EUnetHTA 21 Consortium will cease operating on 16 September 2023. The following information on the closure process is provided:

  • The EUnetHTA website will continue to be available online for a limited amount of time;
  • In case of need for any material, it is recommended to upload it as soon as possible;
  • The EUnetHTA 21 General Secretariat, currently based at the Dutch National Healthcare Institute in the Netherlands, will continue to operate and respond to queries for ten working days after the end of the Service Contract. The general inbox,, will also continue to be operational during this period. The email inbox will no longer be monitored after the ten working days have passed;
  • The HTA Regulation Secretariat at the European Commission will be the contact point for matters related to HTA collaboration under the HTAR. To contact them, the following email is provided:

The EUnetHTA team is currently exploring maintaining the EUnetHTA brand under a different framework in order to facilitate potential future voluntary collaboration. More information about this will be released as and when available.

The full details in English can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.